#China #Shanghai #Drug Approval #Immuno-Oncology #3S Bio

3S Bio Delivers Robust Interim Results for 2026

3S Bio, listed on the Hong Kong Stock Exchange under the symbol 01530.HK, has recently announced its interim financial results for the first half of 2026, highlighting a notable revenue increase and significant advancements in its research and development (R&D) initiatives. With a revenue of RMB 4.53 billion, the company experienced a year-on-year growth of 3.9%. The net profit attributable to equity holders reached RMB 1.15 billion, with an adjusted operating net profit of RMB 1.44 billion, marking a remarkable 26.5% increase compared to the previous year. The financial health of the company appears robust, with total financial resources amounting to RMB 19.4 billion, facilitating further R&D and strategic initiatives.

During this period, 3S Bio secured marketing approvals for core pharmaceutical products across 23 countries, leading to a 43% surge in overseas product sales compared to the prior year. This growth was primarily attributed to the increased market penetration of critical products like rhEPO, Yisaipu, and rhTPO in several emerging markets around the globe.

Strategic Alliances and Breakthrough Innovations

In early 2026, three ground-breaking Class 1 innovative drugs received marketing approvals, demonstrating 3S Bio’s commitment to advancing healthcare solutions. The company has made substantial progress with its multi-therapeutic pipeline, underlining its competitive edge in vital healthcare areas.

PF-08634404 (SSGJ-707), an anti-PD-1/VEGF bispecific antibody, has emerged as a promising candidate in the area of immuno-oncology. Following a strategic partnership with Pfizer, 3S Bio granted global development and commercialization rights for SSGJ-707, with a substantial deal value exceeding US$6 billion. This collaboration not only included a landmark upfront payment of US$1.4 billion but also established a structure for ongoing royalty earnings based on future sales. As of now, multiple clinical trials for SSGJ-707 have commenced worldwide, encompassing various high-prevalence cancers.

Expansion of Innovative Drug Pipeline

3S Bio has reiterated its established R&D strategy with successful launches of several innovative drugs. Among these, Yisaituo® was approved for the treatment of moderate-to-severe plaque psoriasis, while NuPIAO® became the first long-acting recombinant EPO formulation in China, targeting anemia in hemodialysis patients. Additionally, the recent approval of Yisaina®, a monoclonal antibody for acute gouty arthritis, highlights the company's capacity to bring novel solutions to market.

Currently, five additional products are poised for market entry, covering diverse therapeutic areas such as dermatology, ophthalmology, and oncology. These advancements not only position the company for future growth but also solidify its commitment to providing innovative health solutions.

Commitment to Sustainability and ESG Excellence

3S Bio's dedication to sustainable practices has garnered recognition within the industry. The company actively integrates Environmental, Social, and Governance (ESG) principles into its operations. Recently, 3S Bio achieved an upgrade in its ESG rating to “AA”, placing it among the top companies in the biotechnology sector. This recognition underscores the company's commitment to risk management, adherence to compliance, and corporate social responsibility.

Dr. Jing LOU, Chairman and CEO of 3S Bio, remarked on these accomplishments: “The biopharmaceutical sector is a strategic pillar in China, and amidst a shift towards high-quality growth, our innovation-driven approach enhances our competitiveness. Our ongoing focus on oncology and autoimmune diseases will fuel sustained growth.”

In summary, 3S Bio’s interim results for the first half of 2026 not only reflect strong financial performance but also reveal the company's strategic advancements in drug development and commitment to sustainable practices. As the company continues to innovate, its prospects for future growth remain promising.